DDInter16 DDInter1631
A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market.
Safinamide is for the treatment of parkinson's disease. It was approved in Europe in February 2015, and in the United States on March 21, 2017.
Acetohexamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Amcinonide
Acetohexamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Tromethamine
Acetohexamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Acetohexamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bortezomib
Acetohexamide {u} may lead to a major life threatening interaction when taken with {v} Trovafloxacin
Acetohexamide {u} may lead to a major life threatening interaction when taken with {v} Fluconazole
Acetohexamide may cause a minor interaction that can limit clinical effects when taken with Amcinonide
Acetohexamide may cause a minor interaction that can limit clinical effects when taken with Tromethamine
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib
Acetohexamide may lead to a major life threatening interaction when taken with Trovafloxacin
Acetohexamide may lead to a major life threatening interaction when taken with Fluconazole